Protocol Ledger

NCT05183646 · Phase III · RECRUITING

A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB

Interventional Phase III clinical trial protocol NCT05183646 sponsored by Dimerix Bioscience Pty in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-05-30 Enrollment: 286 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05183646
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)286 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05183646
Protocol FieldVerified Registry Value
NCT IdentifierNCT05183646
Consolidated Lead SponsorDimerix Bioscience Pty
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment286 participants (ESTIMATED)
Registered Start Date2022-05-30
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05183646
Hospital Research SiteLocationSite Profile
University of Alabama at BirminghamBirmingham, ALOpen Hospital Dossier ->
Phoenix Children's HospitalPhoenix, AZOpen Hospital Dossier ->
Loma Linda University Medical CenterLoma Linda, CAOpen Hospital Dossier ->
Cedars-Sinai Medical CenterLos Angeles, CAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI